WallStreetZenWallStreetZen

NYSEMKT: PLX
Protalix Biotherapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PLX

Based on 1 analyst offering 12 month price targets for Protalix Biotherapeutics Inc

Min Forecast
$12.00+466.04%
Avg Forecast
$12.00+466.04%
Max Forecast
$12.00+466.04%

Should I buy or sell PLX stock?

Based on 1 analyst offering ratings for Protalix Biotherapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PLX's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates PLX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their PLX stock forecasts and price targets.

PLX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-19

1 of 1

Forecast return on equity

Is PLX forecast to generate an efficient return?

Company
18.56%
Industry
4.51%
Market
135.74%
PLX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PLX forecast to generate an efficient return on assets?

Company
10.87%
Industry
-10.29%
PLX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PLX earnings per share forecast

What is PLX's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.07
Avg 2 year Forecast
$0.11

PLX revenue forecast

What is PLX's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$72.2M+36.81%
Avg 2 year Forecast
$69.7M+32.21%
PLX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PLX revenue growth forecast

How is PLX forecast to perform vs Biotechnology companies and vs the US market?

Company
36.81%
Industry
30.94%
Market
170.38%
PLX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PLX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PLX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PLX$2.12$12.00+466.04%Buy
ABOS$2.38$8.00+236.13%Strong Buy
ANTX$4.68N/AN/A
SABS$3.47$10.75+209.80%Strong Buy
FATE$1.53N/AN/A
View Top Biotech Stocks

Protalix Biotherapeutics Stock Forecast FAQ

Is Protalix Biotherapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSEMKT: PLX) stock is to Buy PLX stock.

Out of 1 analyst, 0 (0%) are recommending PLX as a Strong Buy, 1 (100%) are recommending PLX as a Buy, 0 (0%) are recommending PLX as a Hold, 0 (0%) are recommending PLX as a Sell, and 0 (0%) are recommending PLX as a Strong Sell.

If you're new to stock investing, here's how to buy Protalix Biotherapeutics stock.

What is PLX's earnings growth forecast for 2026-2027?

(NYSEMKT: PLX) Protalix Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 19.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,428.47%.

Protalix Biotherapeutics's earnings in 2026 is -$6,604,000.On average, 3 Wall Street analysts forecast PLX's earnings for 2026 to be $5,696,415, with the lowest PLX earnings forecast at -$4,737,613, and the highest PLX earnings forecast at $16,920,045.

In 2027, PLX is forecast to generate $8,951,509 in earnings, with the lowest earnings forecast at $6,316,817 and the highest earnings forecast at $11,844,031.

What is PLX's revenue growth forecast for 2026-2027?

(NYSEMKT: PLX) Protalix Biotherapeutics's forecast annual revenue growth rate of 36.81% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 170.38%.

Protalix Biotherapeutics's revenue in 2026 is $52,744,000.On average, 3 Wall Street analysts forecast PLX's revenue for 2026 to be $5,814,130,258, with the lowest PLX revenue forecast at $5,089,146,624, and the highest PLX revenue forecast at $6,636,122,150.

In 2027, PLX is forecast to generate $5,618,582,883 in revenue, with the lowest revenue forecast at $4,894,485,537 and the highest revenue forecast at $6,438,077,054.

What is PLX's forecast return on assets (ROA) for 2026-2027?

(NYSEMKT: PLX) forecast ROA is 10.87%, which is higher than the forecast US Biotechnology industry average of -10.29%.

What is PLX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year PLX price target, the average PLX price target is $12.00, with the highest PLX stock price forecast at $12.00 and the lowest PLX stock price forecast at $12.00.

The Wall Street analyst predicted that Protalix Biotherapeutics's share price could reach $12.00 by Mar 19, 2027. The average Protalix Biotherapeutics stock price prediction forecasts a potential upside of 466.04% from the current PLX share price of $2.12.

What is PLX's Earnings Per Share (EPS) forecast for 2026-2027?

(NYSEMKT: PLX) Protalix Biotherapeutics's current Earnings Per Share (EPS) is -$0.08. On average, analysts forecast that PLX's EPS will be $0.07 for 2026, with the lowest EPS forecast at -$0.06, and the highest EPS forecast at $0.21. In 2027, PLX's EPS is forecast to hit $0.11 (min: $0.08, max: $0.15).

What is PLX's forecast return on equity (ROE) for 2026-2027?

(NYSEMKT: PLX) forecast ROE is 18.56%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.